Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial.

Yang, Yang; He, Yingjian; Fan, Zhaoqing; Chen, Xue; Liu, Yiqiang; Zhang, Chao; Jiang, Hongchuan; Wang, Xin; Wang, Xiang; Xie, Fei; Wang, Shu; Luo, Bin; Kang, Hua; Wang, Tao; Jiang, Zefei; Yuan, Peng; Xu, Binhe; Xu, Ling; Liu, Yinhua; Li, Jinfeng; Xie, Yuntao; Wang, Tianfeng; Ouyang, Tao

Yang, Yang; He, Yingjian; Fan, Zhaoqing; Chen, Xue; Liu, Yiqiang; Zhang, Chao; Jiang, Hongchuan; Wang, Xin; Wang, Xiang; Xie, Fei; Wang, Shu; Luo, Bin; Kang, Hua; Wang, Tao; Jiang, Zefei; Yuan, Peng; Xu, Binhe; Xu, Ling; Liu, Yinhua; Li, Jinfeng; Xie, Yuntao; Wang, Tianfeng; Ouyang, Tao.

Afiliação

Yang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
He Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Fan Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China. zhqfan@bjmu.edu.cn.
Chen X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Zhang C; Beijing Chao Yang Hospital, Breast Disease Department, Beijing, China.
Jiang H; Beijing Chao Yang Hospital, Breast Disease Department, Beijing, China.
Wang X; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China.
Wang X; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China.
Xie F; Peking University People's Hospital, Breast Cancer Center, Beijing, China.
Wang S; Peking University People's Hospital, Breast Cancer Center, Beijing, China.
Luo B; Beijing Tsinghua Changgeng Hospital, Breast Disease Department, Beijing, China.
Kang H; Xuan Wu Hospital Capital Medical University, Breast Disease Department, Beijing, China.
Wang T; 307 Hospital of PLA, Breast Cancer Department, Beijing, China.
Jiang Z; 307 Hospital of PLA, Breast Cancer Department, Beijing, China.
Yuan P; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China.
Xu B; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China.
Xu L; Peking University First Hospital, Breast Cancer Center, Beijing, China.
Liu Y; Peking University First Hospital, Breast Cancer Center, Beijing, China.
Li J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Wang T; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Ouyang T; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.

NPJ Breast Cancer ; 9(1): 54, 2023 Jun 21.

Article em En | MEDLINE | ID: mdl-37344451

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: NPJ Breast Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google